Patty Murray%2C official portrait%2C 113th Congress.
(Image by (From Wikimedia) United States Senate, Author: United States Senate) Details Source DMCA
Now that the USA leads the world in Corona virus infected people, we must note a significant development in the effort to medically protect consumers in every nation:
This is really huge news in the Corona virus patent world, which precisely shows the "pressure" on Gilead, partially from my article, partially from OpEdNews Publisher Rob Kall's posting it immediately, and substantially as a result of the article in The Intercept (a reference link to which was included in my article): all of this and more has caused Gilead to decline the long range lucrative Orphan Drug-Rare Disease status granted earlier this week by the FDA and Trump's Big Pharma advice team [which might or might not include Donald Rumsfeld~~~Rumsfeld joined Gilead as a director in 1988 Chairman (1997-2001, and has a long egregious history in the world of profiting hugely off of vaccinations, including Swine Flu, Tamiflu, and Avian Flu)]
Here is my article from two days ago:FDA Gives Gilead Orphan Status on Remdesivir/Coronavirus as "Rare Disease"~Reminiscent of Rumsfeld's Swine Flu Debacle?
These may seem like trivial breakthroughs for consumers but I assure you that it is vital and incisive. I don't have the full picture of all of whom deserve thanks, but I do know that Dr. Betty Martini, Founder Mission Possible International, sent that article by me out to several million people and was sending the entire article out till 3 a.m. Wednesday morning reaching out to physicians, news media all over the world, aspartame activists, and victims of aspartame poisoning; she has lists of tens of thousands of each.
Wednesday afternoon, Gilead caved in and gave up the distinction which they were crowing about just a few days earlier.
Here is an abbreviated version of the news, from International Business Times:
Bowing to critics, Gilead Sciences on Wednesday asked U.S. regulators not to label its COVID-19 treatment candidate an orphan drug, which would have given the company significant tax incentives and a virtual monopoly for years.
The U.S. Food and Drug Administration gave Gilead's remdesivir, which originally was developed to treat Ebola, orphan status earlier this week. The drug is currently undergoing clinical trials to determine whether it is effective and some of the production has been reserved for compassionate use. Sen. Patty Murray, D-Wash., said the FDA designation was misguided. (She nailed that one. Maybe Senator Murray can soon determine just who was doing the misguiding?) Orphan drug status is generally reserved for pharmaceuticals treating diseases affecting 200,000 people or fewer. In a matter of weeks, more than 61,000 Americans have tested positive for the coronavirus. Globally, more than 451,355 have been infected and more than 20,550 have died, including some 800 Americans.
(Note: You can view every article as one long page if you sign up as an Advocate Member, or higher).